Xplore Lifestyle partners with Israeli technology company to launch world’s first medical grade and wearable continuous monitoring Watch: CardiacSense, a boon for arrhythmia/irregular heartbeat care

This is a clinically proven and approved as medical device with EU MDR and CE 2797 certifications.

·        CardiacSense surpassed all US FDA set thresholds on all parameters during trials exhibiting 0.6% False Detection Rate (FDR) as against USFDA-mandated threshold of 2%and with an accuracy of over 99%

Pune (Voice News Service):In a far-reaching development forhealth monitoringparticularly forcardiology in the country, Xplore Lifestyle, country’s leadingand futuristicMedTech solutions provider in collaboration with an Israeli company has come up with the most advanced cardiac and other vital signs monitoring technology in the form of an easy-to-wear watch. Taking wearable technologies to a new level, CardiacSense is the first medical grade continuous vitals monitoring device launchedglobally. The product was launched at Hotel JW Marriott Pune at an event attended by Eyal Copitt and IdoMor from Cardiac Sense, and Pankaj Balwani from Xplore Lifestyle.

Built with cutting edge Israeli biosensing technologies, its patented opto-mechanical sensors when combined with the proprietary PPG, ECG and Artifact sensing Technology and advanced algorithms, the watchcan detect and read heart activity beat-by-beat. As a result, it can detect fatal Arrhythmia like AFib, and notify doctors and family members of patients instantly. It can also be used for patients sufferingshilaa from chronic conditions such as BP (hypertension), Chronic Heart Failure (CHF) and other cardiac conditions.

The watch also has the capability to measurebreath by breath respiratory rate and can track conditions such as COPD and Sleep Apnea. A watch being able to read respiratory rate is again world’s first.

As against anUS FDA-set threshold of maximum 2% False Detection Rate (FDR), CardiacSensehas shownremarkably high accuracy rates with just 0.6% FDR making it the most accurate medical device amongst all wearable devices in the world market. Already armed with a CE certification under European Union’s Medical Device Regulation (MDR), the product is in advanced stages of being approved by the US FDA too.

“Patients with irregular heart rhythms (Arrhythmia) in most cases don’t realize that they may be suffering from some of the life-threatening abnormal heart rhythms. With Atrial Fibrillation being the most serious of arrhythmias (irregular heartbeat) responsible for approximately 70% of ischemic strokes, CardiacSense is able to detect Atrial Fibrillation with over 99% accuracy.With CardiacSense,patients and their doctors will get alerts for life-threatening events.Alsodoctors can look through saved recordings on the Mobile App and cloudfor all vital signs of patients, and will be able to assess what had really happened with the patient during a cardiacevent. This 24/7 continuous monitoringcapability gives very usefulinformation in the hands of doctors who can diagnose and quickly start the right treatment for such patients, said Mr. Pankaj Balwani, the founder & CEO of Xplore Lifestyle.

“For over adecade now, Xplore Lifestyle has been at the forefront of various healthcare technologies introduced in the Indian market. We have an outstanding track record of bringing innovative MedTech devices derived from cutting edge technologies. In fact, Xplore Lifestyle is in the process of launching some more advanced life-saving medical devices forging collaborations with some of the best in the world. These technologies will completely transform the way hospitals and doctors deliver healthcare services to their patients today. Over the years, we have positioned ourselves as specialists in patient and health monitoring technologies and devices.With the launch of CardiacSense, we did not just wish to fill the market gap in terms of providing the most accurate Ambulatory Patient Monitoring Device in the world, we also wish to make people aware of the silent and life-threatening nature of some of the arrhythmiasincluding Atrial Fibrillation and other chronic illnesses,” added Mr Balwani.

The device will be available in India from September 2022.

—